Alkermes Plc (ALKS)

$ALKS Adding today.

$ALKS $BIIB $TAK $AXSM $CNTA also golman sacks has his own agenda ...never trust analysts

Goldman Sachs🏁 $ALKS But/$43. $BIIB $TAK $AXSM JAZZ $CNTA Goldman Sachs said in its initiation report:

Goldman Sachs has updated their rating for Alkermes ( $ALKS ) to Buy with a price target of 43.

$ALKS Outstanding article that hits the mark on ALKS's current state. So if you want to refresh your ALKS insights or learn about ALKS from scratch, this is a must read. https://beyondspx.com/article/alkermes-unlocking-neuroscience-value-through-proprietary-growth-and-a-transformative-pipeline-alks

$ALKS 🥳

$ALKS this dip will be so delicious, bought here🥳

Wall St is expecting 0.38 EPS for $ALKS Q2 [Reporting 07/23 BMO] http://www.estimize.com/intro/alks?chart=historical&metric_name=eps&utm_co

$ALKS With a proven psychiatry portfolio & a high-upside sleep drug in the works, Alkermes is positioned for explosive growth. https://biotechhealthx.com/biotech-news/alkermes-alks-could-be-the-best-neuroscience-stock-to-own-this-decade/

Stifel reitd $ALKS Buy-$42~"We remain Buy on $ALKS into the upcoming NT1 readout for ALKS2680, coming early-3Q. [ $TAK] Bottom line: the risk/reward on this specific catalyst isn't great, simply because investors mostly expect NT1 to be positive. However, our thesis here continues to center around a view that: (1) ALKS2680 is likely to succeed in NT1 and beyond--including in "normal" orexin populations like NT2/IH and (2) the Street's safety concerns with '2680--visual disturbances, etc.--are probably overdone. To this point, assuming the NT1 trial succeeds, safety/tolerability, and nuances around the ALKS2680 dose response, may end up being the most important points with implied readthrough onto prospects in NT2 (data this fall). The other question for NT1 is whether Takeda--with TAK-861--leaves any room for clinical differentiation. Admittedly while we think '2680 is a more potent drug with superior (QD) dosing, the bar is high; there is some, but not much, room on MWT, cataplexy and CGI-I."

$ALKS $BBIO $INCY Strong!

$ALKS Good things are happening here.

$ALKS https://anachart.com/wp-content/uploads/ana_temp/1750161688_soc-img.jpg

UBS has updated their rating for Alkermes ( $ALKS ) to Buy with a price target of 42.

Alkermes just upgraded at UBS, here's why - $ALKS - https://thefly.com/permalinks/entry.php/ALKSid4146368?1750148705C38

$ATAI = Lets say ATAI receives a "Breakthrough Therapy" Designation. How will that effect the pps on a percentage basis? $CYBN $MNMD $CMPS $ALKS

$ALKS Alkermes presenting new research related to ALKS 2680 at SLEEP 2025 Alkermes plans to present new research related to ALKS 2680 at SLEEP 2025, the 38th annual meeting of the Associated Professional Sleep Societies June 8-11 in Seattle. ALKS 2680 is the company's novel, investigational, oral orexin 2 receptor, or OX2R, agonist in phase 2 development as a once-daily treatment for narcolepsy type 1 - NT1 -, narcolepsy type 2 - NT2 - and idiopathic hypersomnia - IH -. Seven abstracts were accepted for poster presentation. The one abstract selected for dual presentation describes quantitative electroencephalography exploratory results from the phase 1b study of ALKS 2680 in patients with NT1, NT2 and IH. Findings demonstrated a statistically significant, wake-associated qEEG profile with ALKS 2680 compared to placebo. In addition, in an oral presentation, Alkermes' VP of Clinical Development, will provide an overview of the ALKS 2680 development program and Alkermes' broader orexin portfolio. Additional presentation highlights include: pooled data from the phase 1b study which showed that single doses of ALKS 2680 were generally well tolerated and led to statistically significant, clinically meaningful improvements in mean sleep latency at all doses tested in patients with NT1, NT2 or IH; results from a cardiac safety analysis in healthy volunteers, which demonstrated a lack of any effects of ALKS 2680 on QTc prolongation, heart rate or cardiac conduction; study design and methods for Vibrance-3, a recently initiated phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to placebo in patients with IH; findings from a retrospective, cross-sectional analysis of the 2021/2023 U.S. National Health and Wellness Survey evaluating the clinical, economic and humanistic burden of narcolepsy.

Needham has adjusted their stance on Alkermes ( $ALKS ), setting the rating to Buy with a target price of 45.

Cantor Fitzgerald reiterated $ALKS Overweight-$43, said "We are providing a brief preview for the P2 Vibrance-1 (NT1, early-3Q25) and Vibrance-2 (NT2, data Fall'25) trial readouts." $TAK $JAZZ $HRMY $CNTA Cantor Fitzgerald added, "The [ $ALKS ] data will be pivotal in de-risking ALKS 2680's profile as a highly selective, QD oral orexin 2 agonist (we say "OX2Rag") with potential best-in-class differentiation. The studies may validate '2680's therapeutic index, leveraging its high selectivity/potency and safety/tolerability profile, which could address unmet needs in both NT1 (orexin-deficient) and NT2 (non-orexin pathophysiology) populations. Cantor Fitzgerald went on to say:

$ALKS CYDY